Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
gene therapy
8
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
8
×
biotech
biogen
clinical trials
fda
glaxosmithkline
medicare
abbvie
amgen
deals
cancer immunotherapy
celgene
crispr
What
bio
roundup
8
×
cancer
crispr
days
democrats
drug
healthcare
ipo
moves
new
news
patients
remains
talk
terms
abbvie’s
acquisitions
ahead
albert
allogene
alzheimer’s
america
approval
august
becker
biggest
billions
biofourmis
biogen
biogen’s
biopharmaceutical
biotech
bourla
bucks
busy
celebrate
ceo
chance
companies
Language
unset
unknown
Current search:
roundup
×
novartis
×
" boston top stories "
×
" wisconsin top stories "
×
" gene therapy "
×
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More